The Role of Hormonal Contraceptives in the Modern Management of Reproductive-age Patients

Cover Page
  • Authors: Iurova M.V.1,2, Kordys A.A.1, Belavina M.A.3, Israilova A.U.1, Aksenova A.V.4
  • Affiliations:
    1. Federal State Budgetary Institution «National Medical Research Center of Obstetrics, Gynecology and Perinatology named after academician V. I. Kulakov» of the Ministry of Health of the Russian Federation
    2. First Moscow State Medical University (Sechenov University) of the Ministry of Health of the Russian Federation
    3. N. I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
    4. First Moscow State Medical University named after I. M. Sechenov of the Ministry of Health of the Russian Federation
  • Issue: No 1 (2025)
  • Pages: 49-54
  • Section: ACTUAL QUESTION
  • URL: https://ogarev-online.ru/2619-0001/article/view/372592
  • ID: 372592

Cite item

Full Text

Abstract

Having a systemic effect, hormonal drugs are one of the most effective therapeutic options in the management of patients of various ages and physiological conditions. A woman’sinterest in contraception can transform into pregnancy planning within a few months, so not only the contraceptive, but also the antiproliferative properties of the drug are important. Family planning and contraception are important aspects of women’shealth that affect virtually every one of them at various stages of life. In today’ssociety, where women are increasingly taking an active part in professional and social life, the need for effective and safe methods of contraception is becoming especially urgent. As an advantage of modern hormonal drugs, it should be noted the possibility of replenishing the folate pool in the body of the expectant mother in combination with contraception. Along with folate, weshould pay attention to sufficient.

About the authors

M. V. Iurova

Federal State Budgetary Institution «National Medical Research Center of Obstetrics, Gynecology and Perinatology named after academician V. I. Kulakov» of the Ministry of Health of the Russian Federation; First Moscow State Medical University (Sechenov University) of the Ministry of Health of the Russian Federation

Email: rectorat@staff.sechenov.ru
ORCID iD: 0000-0002-0179-7635117997
PhD, obstetrician-gynecologist, researcher, assistant of the Department of Obstetrics, Gynecology, Perinatology and Reproductology of IPO 117997, Moscow, 4, Akademika Oparina St.; Moscow

A. A. Kordys

Federal State Budgetary Institution «National Medical Research Center of Obstetrics, Gynecology and Perinatology named after academician V. I. Kulakov» of the Ministry of Health of the Russian Federation

Email: rectorat@staff.sechenov.ru
ORCID iD: 0009-0003-9170-706X
resident Moscow

M. A. Belavina

N. I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: rsmu@rsmu.ru
5th year student 117513, Moscow, Ostrovityanova St., Building 1

A. U. Israilova

Federal State Budgetary Institution «National Medical Research Center of Obstetrics, Gynecology and Perinatology named after academician V. I. Kulakov» of the Ministry of Health of the Russian Federation

Email: rectorat@staff.sechenov.ru
ORCID iD: 0009-0008-8976-5945
resident Moscow

A. V. Aksenova

First Moscow State Medical University named after I. M. Sechenov of the Ministry of Health of the Russian Federation

Email: rectorat@staff.sechenov.ru
ORCID iD: 0009-0003-9962-6854
student 119435, Moscow, 2-4 Bolshaya Pirogovskaya str.

References

  1. Kamani M., Akgor U., Gültekin M. Review of the literature on combined oral contraceptives and cancer. Ecancermedicalscience. 2022; 16: 1416. doi: 10.3332/ecancer.2022.1416
  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Genetic/Familial High-­Risk Assessment: Breast, Ovarian, and Pancreatic Version 3.2024 — February 12, 2024. NCCN.org.
  3. Национальные медицинские критерии приемлемости методов контрацепции (Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5-е изд., 2015»). М., 2023. [National medical eligibility criteria for contraceptive methods (Adapted from the WHO Medical Eligibility Criteria for Contraceptive Use, 5th edition, 2015). Moscow, 2023. (In Russ.)].
  4. Клинические рекомендации «Контрацепция. Наблюдение за применением противозачаточных средств», 2024 (проект). Режим доступа: https://roag-portal.ru/projects_gynecology. [Clinical guidelines «Contraception. Monitoring the use of contraceptives», 2024 (draft). Access mode: https://roag-portal.ru/projects_gynecologyhttps://roag-portal.ru/projects_gynecology. (In Russ.)].
  5. FSRH Guideline. Combined Hormonal Contraception. 2019, Hormonal Contraception. Guideline of the DGGG, OEGGG and SGGG 2020.
  6. Клинические рекомендации «Гиперплазия эндометрия», 2024 (проект). Режим доступа: https://roag-portal.ru/projects_gynecology. [Clinical guidelines «Endometrial hyperplasia», 2024 (draft). Access mode: https://roag-portal.ru/projects_gynecologyhttps://roag-portal.ru/projects_gynecology. (In Russ.)].
  7. Tian Y., Liu Y., Wang G. et al. Endometrial hyperplasia in infertile women undergoing IVF/ICSI: A retrospective cross-­sectional study. J Gynecol Obstet Hum Reprod. 2020: 101780. doi: 10.1016/j.jogoh.2020.101780
  8. Reed S. D., Newton K. M., Clinton W. L. et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009; 200: 678.e1–6.
  9. Urban R. R., Reed S. D. Endometrial hyperplasia: Management and prognosis. UpToDate, 2024.
  10. Fraser I. S., Critchley H. O., Broder M. et al. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011; 29: 383–90.
  11. Клинические рекомендации «Рак тела матки и саркомы матки», 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/460_3. [Clinical guidelines «Uterine body cancer and uterine sarcomas», 2021. Access mode: https://cr.minzdrav.gov.ru/recomend/460_3https://cr.minzdrav.gov.ru/recomend/460_3. (In Russ.)].
  12. Клинические рекомендации «Аномальные маточные кровотечения», 2024 (проект). Режим доступа: https://roag-portal.ru/projects_gynecology. [Clinical guidelines «Abnormal uterine bleeding», 2024 (draft). Access mode: https://roag-portal.ru/projects_gynecologyhttps://roag-portal.ru/projects_gynecology. (In Russ.)].
  13. Wang Y., Nisenblat V., Tao L. et al. Combined estrogen-­progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. J Gynecol Oncol. 2019; 3 (30): e49. doi: 10.3802/jgo.2019.30.e49
  14. Клинические рекомендации «Миома матки», 2024 (проект). Режим доступа: https://roag-portal.ru/projects_gynecology. [Clinical guidelines «Uterine fibroids», 2024 (draft). Access mode: https://roag-portal.ru/projects_gynecologyhttps://roag-portal.ru/projects_gynecology. (In Russ.)].
  15. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol. 2021; 6 (137): e100-e115. doi: 10.1097/AOG.0000000000004401
  16. Grings A. O. et al. Protein expression of estrogen receptors α and β and aromatase in myometrium and uterine leiomyoma. Gynecologic and obstetric investigation. 2012; 2 (73): 113–117.
  17. Stewart E. A. et al. Epidemiology of uterine fibroids: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology. 2017; 10 (124): 1501–1512.
  18. Qin J. et al. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case–control studies. Archives of gynecology and obstetrics. 2013; 1 (288): 139–148.
  19. Becker C. M., Bokor A., Heikinheimo O. et al.; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum Reprod Open. 2022; 2 (2022): hoac009. doi: 10.1093/hropen/hoac009
  20. Zondervan K. T., Becker C. M., Missmer S. A. Endometriosis. N Engl J Med. 2020; 13 (382): 1244–1256. doi: 10.1056/NEJMra1810764
  21. Клинические рекомендации «Эндометриоз», 2024 (проект). Режим доступа: https://roag-portal.ru/projects_gynecology. [Clinical guidelines «Endometriosis», 2024 (draft). Access mode: https://roag-portal.ru/projects_gynecologyhttps://roag-portal.ru/projects_gynecology. (In Russ.)].
  22. ESHRE guideline: endometriosis. Human Reproduction Open. 2022: 1–26. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951218/ (accessed 21 June 2024).
  23. Клинические рекомендации «Предменструальный синдром», 2024 (проект). Режим доступа: https://roag-portal.ru/projects_gynecology. [Clinical guidelines «Premenstrual syndrome», 2024 (draft). Access mode: https://roag-portal.ru/projects_gynecologyhttps://roag-portal.ru/projects_gynecology. (In Russ.)].
  24. Management of Premenstrual Disorders: ACOG Clinical Practice Guideline No. 7. Obstetrics and Gynecology. 2023; 6 (142): 1516–1533.
  25. de Wit A. E., de Vries Y. A., de Boer M. K. Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials. American Journal of Obstetrics and Gynecology.2021; 6 (225): 624–633.
  26. Ma S., Song S. J. Oral contraceptives containing drospirenone for premenstrual syndrome. The Cochrane Database of Systematic Reviews.2023; 6 (6): CD006586.
  27. Yonkers K. A., Brown C., Pearlstein T. B. et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics and Gynecology.2005; 3 (106): 492–501.
  28. Прилепская В. Н., Ледина А. В. Предменструальный синдром: эффективность лечения дроспиренонсодержащим контрацептивным препаратом. Медицинский совет. 2015; 9. Режим доступа: https://cyberleninka.ru/article/n/predmenstrualnyy-­sindrom-effektivnost-­lecheniya-drospirenon-­soderzhaschim-kontratseptivnym-­preparatom (дата обращения: 04.09.2024). [Prilepskaya V. N., Ledina A. V. Premenstrual syndrome: the effectiveness of treatment with a drospirenone-­containing contraceptive drug. Medical Council. 2015; 9. Available at: https://cyberleninka.ru/article/n/predmenstrualnyy-­sindrom-effektivnost-­lecheniya-drospirenon-­soderzhaschim-kontratseptivnym-­preparatom (accessed 09 April 2024). (In Russ.)].
  29. Almeida O. P., Ford A. H., Flicker L. Systematic review and meta-analysis of randomized placebo-­controlled trials of folate and vitamin B12 for depression. International Psychogeriatrics.2015; 5 (27): 727–737.
  30. Bender A., Hagan K. E., Kingston N. The association of folate and depression: A meta-analysis. Journal of Psychiatric Research. 2017; 95: 9–18.
  31. Клинические рекомендации «Аменорея и олигоменорея», 2024 (проект). Режим доступа: https://roag-portal.ru/projects_gynecology. [Clinical guidelines «Amenorrhea and oligomenorrhea», 2024 (draft). Access mode: https://roag-portal.ru/projects_gynecologyhttps://roag-portal.ru/projects_gynecology. (In Russ.)].
  32. Клинические рекомендации «Синдром поликистозных яичников», 2024 (проект). Режим доступа: https://roag-portal.ru/projects_gynecology. [Clinical guidelines «Polycystic ovary syndrome», 2024 (draft). Access mode: https://roag-portal.ru/projects_gynecologyhttps://roag-portal.ru/projects_gynecology. (In Russ.)].
  33. Forslund M., Melin J., Alesi S. et al. Different kinds of oral contraceptive pills in polycystic ovary syndrome: A systematic review and meta-analysis. July 2023. European Journal of Endocrinology. 2023; 189: S1–S16. doi: 10.1093/ejendo/lvad082
  34. Gadalla M. A., Norman R. J., Tay C. T. et al. Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews. Int J Fertil Steril. 2020; 4 (13): 257–270. doi: 10.22074/ijfs.2020.5608
  35. Aversa A., La Vignera S., Rago R. et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front. Endocrinol. 2020; 11: 516. doi: 10.3389/fendo.2020.00516
  36. Alesi S., Ee C., Moran L. J. et al. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. Adv Nutr. 2022; 4 (13): 1243–1266.
  37. Mondal K., Chakraborty P., Kabir S. N. Hyperhomocysteinemia and hyperandrogenemia share PCSK9-LDLR pathway to disrupt lipid homeostasis in PCOS. Res Commun. 2018 Apr 13. pii: S0006–291X (18)30847–7
  38. Yildizhan R., Gokce A. I., Yildizhan B. et al. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. Gynecol Endocrinol. 2015; 5 (31): 396–400. doi: 10.3109/09513590.2015.1006187 https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4e56615d-5a2f-4f67-a3c6–1aaea9585344.
  39. Amiri M., Nahidi F., Bidhendi-Yarandi R. et al. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. Hum Reprod. 2020; 1 (35): 175–186. HYPERLINK «https://doi.org/10.1093/humrep/dez255» doi: 10.1093/humrep/dez255
  40. Прилепская В. Н., Назаренко Е. Г. Современная контрацепция: от профилактики к эффективному лечению. Медицинский оппонент. 2018; 2 (2): 62–68. [Prilepskaya V. N., Nazarenko E. G. Modern contraception: from prevention to effective treatment. Meditsinskiy opponent=Medical opponent. 2018; 2 (2): 62–68. (In Russ.)]. https://proffopponent.ru/sample-page/zhurnal-2–2018/
  41. Прилепская В. Н. Эволюция контрацепции в России. Медицинский оппонент. 2018; 4 (4): 16–21. [Prilepskaya V. N. The evolution of contraception in Russia. Meditsinskiy opponent=Medical opponent. 2018; 4 (4): 16–21. (In Russ.)]. https://proffopponent.ru/meditsinskie-­publikacii/o-zhurnale/4–2018/

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).